Zenbao Technology (688797.SH): The final online issuance lottery rate is 0.0217%.

17:23 14/06/2026

Zhenbao Technology (688797.SH) announcement, according to the data provided by the Shanghai Stock Exchange, the number of valid online subscription households for this online issuance is 7,123,286 households, the number of valid subscription shares is 57,133,168,000 shares, and the preliminary online issuance oversubscription rate is 0.01630752%. Due to the preliminary oversubscription ratio of approximately 6,132.14 times for this online issuance, exceeding 100 times, the issuer and underwriters (lead underwriters) have decided to initiate a callback mechanism. After the callback mechanism is activated, the final online issuance winning rate will be 0.02174394%.

Zhenbao Technology (688797.SH) announcement, according to the data provided by the Shanghai Stock Exchange, the number of valid subscription users for this online issuance is 7,123,286, the valid number of shares subscribed is 57,133,168,000, and the preliminary online issuance winning rate is 0.01630752%. Due to the preliminary valid subscription multiple for this online issuance being approximately 6,132.14 times, exceeding 100 times, the issuer and the underwriter (lead underwriter) have decided to initiate a callback mechanism. After the callback mechanism is initiated, the final online issuance winning rate is 0.02174394%.

SAMSONITE (01910) issued a total of 1.83396 million shares under the share award plan.

WEIHAI BANK (09677) signs H-share subscription agreement with Hengyuan Holdings.

GENSCRIPT BIO(01548): The legendary potential "First in Class" intracellular CD19/CD20 dual-target CAR-T therapy LB2501 has obtained clinical conceptual validation in relapsed/refractory B-cell Non-Hodgkin's lymphoma.

SAMSONITE (01910) issued a total of 1.83396 million shares under the share award plan.

WEIHAI BANK (09677) signs H-share subscription agreement with Hengyuan Holdings.